ArticleCPT: pharmacometrics & systems pharmacology2014
A review of mixed-effects models of tumor growth and effects of anticancer drug treatment used in population analysis.
Article in CPT: pharmacometrics & systems pharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
100 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Structural identifiability for mathematical pharmacology: models of myelosuppression.Journal of pharmacokinetics and pharmacodynamics · 2018Pooled it
- Joint modeling of tumor dynamics and progression-free survival in advanced breast cancer: Leveraging data from amcenestrant early phase I-II trials.CPT: pharmacometrics & systems pharmacology · 2024Trial
- Contribution of machine learning to tumor growth inhibition modeling for hepatocellular carcinoma patients under Roblitinib (FGF401) drug treatment.CPT: pharmacometrics & systems pharmacology · 2022Trial
- Early predictions of response and survival from a tumor dynamics model in patients with recurrent, metastatic head and neck squamous cell carcinoma treated with immunotherapy.CPT: pharmacometrics & systems pharmacology · 2021Trial
- Longitudinal analysis of organ-specific tumor lesion sizes in metastatic colorectal cancer patients receiving first line standard chemotherapy in combination with anti-angiogenic treatment.Journal of pharmacokinetics and pharmacodynamics · 2020Trial
- Modeling Tumor Growth and Treatment Resistance Dynamics Characterizes Different Response to Gefitinib or Chemotherapy in Non-Small Cell Lung Cancer.CPT: pharmacometrics & systems pharmacology · 2020Trial
- Population exposure-response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma.Cancer chemotherapy and pharmacology · 2018Trial
- Assessing Similarity Among Individual Tumor Size Lesion Dynamics: The CICIL Methodology.CPT: pharmacometrics & systems pharmacology · 2018Trial
- A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients.CPT: pharmacometrics & systems pharmacology · 2017Trial
- Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer.Clinical pharmacokinetics · 2017Trial
- Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer.Annals of oncology : official journal of the European Society for Medical Oncology · 2016Trial
- PK-PD modeling of individual lesion FDG-PET response to predict overall survival in patients with sunitinib-treated gastrointestinal stromal tumor.CPT: pharmacometrics & systems pharmacology · 2016Trial
- Model-Informed Decision Making from Drug Discovery to Reimbursement: A Roadmap for Clinical Pharmacology in Value-Based Healthcare.Journal of clinical pharmacology · 2026Review
- The Empirical Bayes Variational Autoencoder-A Neural ODE Approach for Population Modeling in Pharmacology.CPT: pharmacometrics & systems pharmacology · 2026Article
- Longitudinal Analysis of Manually and Automatically Classified Circulating Tumor Biomarkers and their Prediction of Survival in Metastatic Colorectal Cancer.Clinical pharmacology and therapeutics · 2026Article
- A Systematic Comparative Analysis of Tumor Size Models Based on Erlotinib Clinical Data in Advanced NSCLC.CPT: pharmacometrics & systems pharmacology · 2025Article
- A memory-driven reinforcement learning model of phenotypic adaptation for anticipating therapeutic resistance in prostate cancer.bioRxiv : the preprint server for biology · 2025Article
- Tutorial on Conditional Simulations With a Tumor Size-Overall Survival Model to Support Oncology Drug Development.CPT: pharmacometrics & systems pharmacology · 2025Article
- Advancing cancer drug development with mechanistic mathematical modeling: bridging the gap between theory and practice.Journal of pharmacokinetics and pharmacodynamics · 2024Review
- Deep reinforcement learning identifies personalized intermittent androgen deprivation therapy for prostate cancer.Briefings in bioinformatics · 2024Article
40 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Population modeling of tumor size dynamics has recently emerged as an important tool in pharmacometric research. A series of new mixed-effects models have been reported recently, and we present herein a synthetic view of models with published mathematical equations aimed at describing the dynamics of tumor size in cancer patients following anticancer drug treatment. This selection of models will constitute the basis for the Drug Disease Model Resources (DDMoRe) repository for models on oncology.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.